Soft Tissue Sarcoma Clinical Trial
Official title:
A Randomized Discontinuation Study of Brivanib Alaninate (BMS-582664) Versus Placebo in Subjects With Advanced Tumors
The purpose of this study is to determine if gastric/esophageal, lung, pancreatic, bladder and sarcoma patients show benefit from brivanib treatment. Patients who clearly do, stay on treatment. Those in which it is unclear will be randomized to continue or withdraw treatment to determine whether that benefit is related to brivanib
Status | Completed |
Enrollment | 597 |
Est. completion date | December 2012 |
Est. primary completion date | February 2012 |
Accepts healthy volunteers | No |
Gender | Both |
Age group | 18 Years and older |
Eligibility |
For additional information, please contact the BMS oncology clinical trial information
service at 855-216-0126 or email MyCancerStudyConnect@emergingmed.com. Please visit
www.BMSStudyConnect.com for more information on clinical trial participation. Inclusion Criteria: - Life expectancy at least 3 months - Diagnosis of a solid tumor which is unresectable in which no approved effective therapy exists or for subjects who are intolerable to such therapy. The initial enrollment will focus on non-small cell lung, gastric/esophageal adenocarcinoma, soft tissue sarcoma, transitional cell carcinoma, and pancreatic cancer including ampulla of Vater tumors - Adequate tumor sample - Adequate recovery (baseline or Grade 1) from recent therapy. At least 1 week must have elapsed from the time of a minor surgery, and at least 8 weeks for major surgery or radiation therapy Exclusion Criteria: - Subjects with known brain metastasis. - Subjects with signs or symptoms suggestive of brain metastasis are not eligible unless brain metastases are ruled out by CT or MRI Medical History and Concurrent Diseases: - History of thrombo-embolic disease within the last six months requiring therapeutic anticoagulation - Subjects with history of poor wound healing or non healing ulcers - Uncontrolled or significant cardiovascular disease Allergies and Adverse Drug Reactions: - History of allergy to brivanib its drug class, or related compounds Prohibited Treatments and/or Therapies: - Exposure to any investigational drug within 4 weeks of enrollment - Other concurrent chemotherapy, hormonal therapy, immunotherapy regimens or radiotherapy, standard or investigational. Subjects may continue to receive hormone replacement therapy - Prior exposure to brivanib |
Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment
Country | Name | City | State |
---|---|---|---|
Argentina | Local Institution | Buenos Aires | |
Argentina | Local Institution | Capital Federal | Buenos Aires |
Argentina | Local Institution | Capital Federal | Buenos Aires |
Argentina | Local Institution | Capital Federal | Buenos Aires |
Belgium | Local Institution | Brussel | |
Belgium | Local Institution | Bruxelles | |
Belgium | Local Institution | Bruxelles | |
Canada | Local Institution | Edmonton | Alberta |
Canada | Local Institution | Toronto | Ontario |
France | Local Institution | Paris | |
France | Local Institution | Paris Cedex 13 | |
Germany | Local Institution | Freiburg | |
Germany | Local Institution | Halle/saale | |
Netherlands | Local Institution | Maastricht | |
Netherlands | Local Institution | Rotterdam | |
Netherlands | Local Institution | Utrecht | |
Poland | Local Institution | Gdansk | |
United Kingdom | Local Institution | Glasgow, Scotland | Strathclyde |
United Kingdom | Local Institution | Surrey | |
United States | Sidney Kimmel Comprehensive Cancer Center At Johns Hopkins | Baltimore | Maryland |
United States | University Of Chicago | Chicago | Illinois |
United States | Northshore Univ. Healthsystem | Evanston | Illinois |
United States | Memorial Sloan Kettering Cancer Center | New York | New York |
United States | Memorial Sloan Kettering Cancer Ctr | New York | New York |
United States | University Of Pennsylvania | Philadelphia | Pennsylvania |
Lead Sponsor | Collaborator |
---|---|
Bristol-Myers Squibb |
United States, Argentina, Belgium, Canada, France, Germany, Netherlands, Poland, United Kingdom,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Radiographic imaging and clinical evaluation will be used for tumor assessment | every 6 weeks | No | |
Secondary | Safety profiles | ongoing throughout trial | Yes | |
Secondary | Disease response rate | determined June 2010 | No | |
Secondary | Disease control rate | determined June 2010 | No | |
Secondary | Pharmacokinetics | determined June 2010 | No | |
Secondary | Pharmacodynamics | determined June 2010 | No | |
Secondary | Biomarkers | determined June 2010 | No |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT02910895 -
A Platform of Patient Derived Xenografts (PDX) and 2D/3D Cell Cultures of Soft Tissue Sarcomas (STS)
|
N/A | |
Recruiting |
NCT05621668 -
A First-In-Human Phase 1 Trial of T-Cell Membrane-Anchored Tumor Targeted Il12 (Attil12)- T-Cell Therapy in Subjects With Advanced/Metastatic Soft Tissue and Bone Sarcoma
|
Phase 1 | |
Active, not recruiting |
NCT04032964 -
Dose Finding Study of L19TNF and Doxorubicin in Patients With STS
|
Phase 1 | |
Active, not recruiting |
NCT04577014 -
Retifanlimab (Anti-PD-1 Antibody) With Gemcitabine and Docetaxel in Patients With Advanced Soft Tissue Sarcoma
|
Phase 1/Phase 2 | |
Completed |
NCT01650077 -
Therapeutic Response of Patients With Soft Tissue Sarcoma According to CHOI Criteria
|
||
Withdrawn |
NCT04906876 -
A Phase 2 Study of 9-ING-41Combined With Chemotherapy in Adolescents and Adults With Advanced Sarcomas
|
Phase 2 | |
Terminated |
NCT02890368 -
Trial of Intratumoral Injections of TTI-621 in Subjects With Relapsed and Refractory Solid Tumors and Mycosis Fungoides
|
Phase 1 | |
Terminated |
NCT02628535 -
Safety Study of MGD009 in B7-H3-expressing Tumors
|
Phase 1 | |
Completed |
NCT02204111 -
Patient Directed Intervention to Improve the Quality of Life for Patients With Soft Tissue Sarcoma
|
||
Withdrawn |
NCT01663090 -
Ferumoxytol-Enhanced MRI in Adult/Pedi Sarcomas
|
N/A | |
Completed |
NCT01259375 -
Amrubicin Chemotherapy as First Line in Metastatic or Unresectable Soft Tissue Sarcoma
|
Phase 2 | |
Completed |
NCT01440088 -
A Trial of TH-302 in Combination With Doxorubicin Versus Doxorubicin Alone to Treat Patients With Locally Advanced Unresectable or Metastatic Soft Tissue Sarcoma
|
Phase 3 | |
Completed |
NCT01106872 -
Bevacizumab, Chemotherapy and Valproic Acid in Advanced Sarcomas
|
Phase 1 | |
Recruiting |
NCT00753727 -
Sunitinib and Radiation in Patients With Resectable Soft-tissue Sarcoma
|
Phase 1/Phase 2 | |
Terminated |
NCT00755261 -
Phase II Study of Doxorubicin and Avastin® in Sarcoma.
|
Phase 2 | |
Completed |
NCT00580320 -
Safety Study of Dacarbazine and Bortezomib in Melanoma and Soft Tissue Sarcoma
|
Phase 1 | |
Completed |
NCT00611078 -
Environmental Pollutants and the Risk of Soft Tissue Sarcoma: A Pilot Study
|
N/A | |
Completed |
NCT03452644 -
US-Guided Biopsy in the Diagnosis of Musculoskeletal Soft-Tissue Tumors
|
||
Recruiting |
NCT05539677 -
Biobank and Register of Patients With Agresive Tumors for Translational and Analytical Research
|
||
Terminated |
NCT03520959 -
A Phase 3, Randomized, Double-blind, Placebo-controlled Study For Subjects With Locally-advanced Unresectable or Metastatic Synovial Sarcoma (V943-003, IMDZ-04-1702)
|
Phase 3 |